We are currently assessing the blood and tumor samples from the patients treated with BriaVax™ (from the preliminary clinical trials) using cutting-edge technologies including gene expression analysis, and proteomics (i.e., defined as the large-scale study of the structure and function of proteins).
We plan to further validate our findings using blood and tumor samples from the patients treated with BriaVax™ in the upcoming clinical trials.
Based on the expression of specific biomarkers in the responder vs the non-responder patients, we are planning to define the molecular fingerprint of the patients for which the vaccine would be highly effective, and use this fingerprint to develop a companion diagnostic product, called BriaDxTM, to identify this subset of patients.
By using BriaDxTM to select the responder patients (i.e. the patients who would most likely benefit from the vaccine), and treating them, we expect to improve the likelihood of clinical trial success for BriaVaxTM– to bring hope to thousands of cancer patients with few-to-no treatment options.